Your browser doesn't support javascript.
loading
Cost of achieving HbA1c and weight loss treatment targets with IDegLira vs insulin glargine U100 plus insulin aspart in the USA.
Billings, L K; Mocarski, M; Basse, A; Hunt, B; Valentine, W J; Jodar, E.
Afiliação
  • Billings LK; Division of Endocrinology and Metabolism, NorthShore University HealthSystem, Skokie, IL, USA.
  • Mocarski M; Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, IL, USA.
  • Basse A; Value Evidence and Outcomes, Novo Nordisk Inc., Plainsboro, NJ, USA.
  • Hunt B; Market Access-Region AAMEO, Novo Nordisk Pharma Gulf FZ-LLC, Dubai, United Arab Emirates.
  • Valentine WJ; Health Economics, Ossian Health Economics and Communications, Basel, Switzerland, hunt@ossianconsulting.com.
  • Jodar E; Health Economics, Ossian Health Economics and Communications, Basel, Switzerland, hunt@ossianconsulting.com.
Clinicoecon Outcomes Res ; 11: 271-282, 2019.
Article em En | MEDLINE | ID: mdl-30962697
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Idioma: En Revista: Clinicoecon Outcomes Res Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Idioma: En Revista: Clinicoecon Outcomes Res Ano de publicação: 2019 Tipo de documento: Article